Industry Bulletins | February 6, 2019
Pear Therapeutics Raises $64 Million, Launches Prescription App For Opioid Use-Related Addiction Disorder
Pear Therapuetics (Pear) recently raised $64 million, in addition to launching a new prescription app for opioid use-related addiction disorder. The news comes shortly after the organization recently received clearance from the U.S. Food and Drug Administration (FDA) for reSET-O, its prescription software for the treatment of opioid use-related addiction disorder.
It is anticipated that the funding will go towards expansion of Pear’s global reach, in addition to helping the organization acquire new assets and bolster its development of products aimed at conditions such as schizophrenia. The organization continues its uphill battle to convince provider . . .